Cardiovascular Diseases (CVD)DDM-TRAINNCT07238036
Data Donation Model for Inclusive Cardiovascular Prevention Using the TRAIN Health Platform
An observational study of Cardiovascular Diseases (CVD), run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).
Trial summary
Cardiovascular disease (CVD) is the leading cause of death in the Netherlands and worldwide. While prevention strategies have improved, many population groups, including women, individuals with a migration background, and people with lower socioeconomic status, remain underrepresented in cardiovascular research and… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cardiovascular Diseases (CVD)
- What is being tested?
- Digital Lifestyle Feedback Module (optional)
- How many people
- 450 participants
- Where
- No sites listed yet
- Study dates
- Jan 2026to 1 Apr 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Adults from the general population voluntarily participating in the TRAIN Health Awareness Platform under the Data Donation Model (DDM). Participants may be healthy or have known cardiovascular risk factors such as hypertension, diabetes, or obesity. Recruitment occurs via digital enrolment, primary care outreach, and community organisations. Participation is nationwide and decentralised, with data collection entirely digital and no site-based visits.
Who may be able to join
- Adults (≥18 years)
- Access to a smartphone, tablet, or computer with internet connection.
- Ability to provide electronic informed consent (in Dutch or with supported translation).
- Willingness to contribute lifestyle, health, and/or wearable data through the TRAIN Health Awareness Platform.
- Optional: interest in participating in the 12-week TRAIN Heart Journey for personalised lifestyle feedback.
Who cannot join
- Inability to provide informed consent, even with support.
- Severe cognitive or psychiatric impairment limiting safe participation.
- Inability to use digital devices, even with assistance.
- Concurrent participation in another behavioural or interventional study that could interfere with data collection.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: The Data Donation Model: Redefining Citizen Participation in Inclusive Cardiovascular Prevention and Care
Cardiovascular disease (CVD) is the leading cause of death in the Netherlands and worldwide. While prevention strategies have improved, many population groups, including women, individuals with a migration background, and people with lower socioeconomic status, remain underrepresented in cardiovascular research and prevention programs. As a result, current risk prediction models and lifestyle recommendations are based largely on homogeneous datasets that do not reflect real-world diversity. This structural imbalance limits the generalisability of evidence and contributes to persistent health disparities.
The Data Donation Model (DDM) aims to address this gap by introducing a citizen-led, transparent, and participatory approach to data sharing for cardiovascular prevention and health research. In this model, individuals voluntarily contribute their lifestyle, behavioural, and wearable/app data for research while maintaining full control over consent and use. The DDM incorporates dynamic electronic consent, granular sharing options, and transparency dashboards that allow participants to view how their data contribute to ongoing research projects. This participatory design strengthens trust, autonomy, and inclusiveness in data governance.
Read more
This study evaluates the feasibility, inclusiveness, and acceptability of implementing the DDM at scale within the general population. It forms the pilot phase of a broader national data donation infrastructure coordinated by Amsterdam UMC in collaboration with the TRAIN Health Awareness Platform (technical partner) and community organisations. Approximately 450 participants will take part in this first phase, with future expansion planned up to 10,000 citizens.
Participants can connect any wearable device or health app (such as a smart ring, smartwatch, or fitness tracker) to the TRAIN platform and complete short digital questionnaires on lifestyle, sleep, stress, and wellbeing. All participants can donate data for up to 5 years, with the freedom to stop or modify consent at any time. An optional 12-week TRAIN Heart Journey provides guided feedback on physical activity, stress, and recovery patterns, but participation in this module is not required for data donation.
The main outcomes are (1) feasibility and acceptability of the DDM (recruitment, retention, adherence, and user satisfaction), (2) inclusiveness of participation across demographic groups, and (3) trust and engagement with science and data governance. Secondary outcomes include behavioural and physiological changes (activity, sleep, stress) and self-efficacy. Exploratory analyses will evaluate long-term engagement and, for consenting participants, linkage with official mortality data from Statistics Netherlands (CBS).
The findings will inform future national strategies for equitable, citizen-driven cardiovascular prevention and contribute to developing inclusive guidelines based on real-world data from diverse populations.
Read the detailed description
Background and Rationale Cardiovascular disease (CVD) remains the leading global cause of mortality. Although preventive strategies have advanced, many population groups continue to be structurally underrepresented in research, including people with a migration background, lower socioeconomic status, lower health literacy, and women. As a result, current datasets and risk prediction models do not accurately reflect population diversity, which limits generalisability and contributes to persistent health inequities.
The Data Donation Model (DDM) aims to address these gaps by offering a citizen-driven, transparent approach to sharing lifestyle, behavioural, and wearable/app-derived health data for preventive cardiovascular research. The DDM allows participants to maintain full control over data use through dynamic electronic consent, granular sharing settings, and real-time insight into how their data contribute to research. This approach operationalises ethical principles of autonomy, transparency, and reciprocity, and aligns with modern frameworks for Responsible Data Stewardship and FAIR/Open Science.
Study Purpose This pilot study evaluates whether the DDM can be implemented at scale within the general population. The focus is on operational feasibility, user experience, inclusiveness of participation, and engagement with dynamic consent tools. Results will guide the development of a long-term, citizen-governed data infrastructure for cardiovascular prevention research.
Study Design This is a prospective, observational cohort study with digital enrolment and follow-up. Participation is open to adults from the general population without recruitment through clinical centres. The study infrastructure is hosted on the TRAIN Health Awareness Platform, which facilitates data donation and device/app integration. Approximately 450 participants will be enrolled during this pilot phase.
Participants voluntarily connect one or more wearable devices or health applications of their choice. They also complete periodic questionnaires via the platform. An optional 12-week digital lifestyle module ("TRAIN Heart Journey") is available but not assigned as part of the research design. Data donation may continue for up to five years, depending on individual consent preferences.
Procedures and Data Streams
After electronic informed consent, participants gain access to a personal dashboard where they can:
connect their chosen wearable(s) or health app(s);
manage consent settings;
complete lifestyle and wellbeing questionnaires;
monitor their own engagement and data-sharing status.
Collected data include device-generated behaviour and wellbeing indicators (e.g., activity metrics, sleep patterns, physiological parameters depending on device type), as well as digital questionnaire responses. No biospecimens are collected, and no identifiable data are used for analysis; all data are pseudonymised at source.
Analytical Framework Feasibility will be evaluated using technical performance indicators (data transmission stability, completeness), recruitment and retention characteristics, and participant engagement metrics. Inclusiveness will be assessed using demographic distributions and literacy indicators. Exploratory analyses will focus on long-term participation patterns and-where separately consented-linkage to national mortality records via secure legal frameworks.
Quantitative analyses may include longitudinal modelling of device-based behavioural and physiological signals and descriptive analysis of user-platform interactions. Qualitative and mixed-methods analyses may be used to explore trust, transparency, and participant experience with the DDM.
Data Management and Protection All data handling complies with the General Data Protection Regulation (GDPR). Data are stored in a secure, Health-RI-aligned cloud environment using encryption, pseudonymisation, and role-based access controls. Participants may modify or withdraw consent at any time through the dynamic consent interface. Optional linkage to external datasets (e.g., mortality data) requires additional explicit consent.
Ethical Considerations The Medical Ethics Review Committee determined that the study does not fall under the Dutch Medical Research Involving Human Subjects Act (non-WMO). The study does not involve investigational products or assigned interventions and poses minimal risk. Participation is voluntary and withdrawal has no consequences.
Dissemination Results will be disseminated through peer-reviewed publications, scientific conferences, and citizen-focused communication channels facilitated by the TRAIN Health Awareness Platform and partner community organisations. Insights from this pilot will inform the subsequent scale-up of a national, citizen-driven data donation infrastructure designed to support equitable, population-representative cardiovascular prevention.
- Conditions
- Cardiovascular Diseases (CVD)
- Being tested
- Digital Lifestyle Feedback Module (optional)
- Keywords
- cardiovascular prevention, data donation, citizen science, health equity, participatory research, digital health, wearable data, lifestyle monitoring, trust in science, inclusiveness, population health, prevention research, FAIR data, Open Science
- Medical subject headings
- Cardiovascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Digital Lifestyle Feedback Module (optional)Other
An optional 12-week digital feedback module offered within the TRAIN platform to participants who choose to engage with guided lifestyle support. This is not an assigned intervention but part of the broader participatory data-donation framework.
| Study group | Role | What they receive |
|---|---|---|
| DDM General Population Cohort | This cohort includes adults residing in the Netherlands who voluntarily participate in the Data Donation Model (DDM) through the TRAIN Health Awareness Platform. Participants provide electronic informed consent, connect wearable devices or health apps, and share lifestyle and wellbeing data for up to five years. An optional 12-week TRAIN Heart Journey module offers guided feedback on activity, sleep, and stress, but participation in this module is not required for data donation.
Participants can modify or withdraw consent at any time. No randomisation, assignment, or blinding is used. Receives: Other: Digital Lifestyle Feedback Module (optional) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Recruitment Rate
Number of participants enrolled per month during the active recruitment period. Recruitment rate reflects the feasibility of enrolling adults from the general population into the Data Donation Model (DDM) via the TRAIN Health Awareness Platform.
Unit of Measure: Participants per month
Measured: From study start until end of recruitment (anticipated 12 months).
Retention Rate at 12 Weeks
Proportion of enrolled participants who complete the 12-week follow-up period with at least one questionnaire assessment. This measure reflects the feasibility of retaining participants in a fully digital observational study.
Unit of Measure: Percentage of participants (%)
Measured: From enrolment to 12 weeks after enrolment.
Adherence to Wearable and App Use
Proportion of follow-up days with any recorded wearable or app data (e.g., activity, sleep, or heart-rate-derived signals), calculated per participant and summarised at group level. This measure reflects adherence to using the connected device(s) and the TRAIN platform in daily life.
Unit of Measure: Percentage of follow-up days with data (%)
Measured: From enrolment to 12 weeks after enrolment.
Wearable Data Completeness
Proportion of expected data points that are successfully captured and stored for each participant over the 12-week period, based on predefined minimum criteria for valid days (e.g., ≥1 full day of activity and sleep data). This reflects the technical feasibility of continuous data capture within the Data Donation Model.
Unit of Measure: Percentage of expected data points (%)
Measured: From enrolment to 12 weeks after enrolment.
Participant Satisfaction Score
Overall satisfaction with the Data Donation Model and the TRAIN platform, measured using a brief user experience questionnaire with items rated on a 5-point Likert scale (1 = strongly disagree to 5 = strongly agree). The primary outcome is the mean total score; higher scores indicate greater satisfaction and acceptability.
Unit of Measure: Mean score on a 1-5 Likert scale (points)
Measured: At 12 weeks after enrolment.
Secondary outcomes (12)
Change in Daily Step Count
Description: Change in total number of steps per day recorded by connected wearable devices.
Unit of Measure: Steps per day
Measured: Baseline to 12 weeks.
Change in Active Minutes per Day
Description: Change in daily minutes classified as "active" or moderate-to-vigorous activity by the wearable device.
Unit of Measure: Minutes per day
Measured: Baseline to 12 weeks.
Change in Heart Rate Variability
Description: Change in daily HRV as measured by the wearable device, reflecting autonomic balance and recovery.
Unit of Measure: Milliseconds (ms)
Measured: Baseline to 12 weeks.
Change in Resting Heart Rate
Description: Change in resting heart rate based on valid daily RHR recordings from the wearable device.
Unit of Measure: Beats per minute (bpm)
Measured: Baseline to 12 weeks.
Change in Sleep Efficiency
Change in sleep efficiency (total sleep time ÷ time in bed), derived from wearable algorithms.
Unit of Measure: Percentage (%)
Measured: Baseline to 12 weeks.
Change in Health-Related Quality of Life (EQ-5D-5L)
Change in health-related quality of life measured using the EuroQoL EQ-5D-5L instrument (range: 5-25; higher scores indicate worse health).
Unit of Measure: Score (points)
Measured: Baseline to 12 weeks after enrolment.
Change in Self-Efficacy (GSES)
Description: Change in perceived self-efficacy measured with the General Self-Efficacy Scale (10-40; higher scores indicate better self-efficacy).
Unit of Measure: Score (points)
Measured: Baseline to 12 weeks.
Inclusiveness of Participation
Representation and adherence will be analysed across demographic and literacy strata (sex, migration background, socioeconomic status, and health literacy).
The Health Literacy Questionnaire (HLQ) and demographic data will characterise diversity and identify barriers to engagement.
Unit of Measure: Proportion of participants (%)
Measured: During and after completion of 12-week period.
Change in Trust in Medical Research
Description: Change in trust using adapted items from the Trust in Medical Researchers scale (range: typically 5-25; higher scores indicate more trust).
Unit of Measure: Score (points)
Measured: Baseline and 12 weeks.
Change in Perceived Transparency
Description: Change in perceived transparency using items adapted from validated public attitudes toward data-sharing instruments (range varies by item; higher scores indicate greater perceived transparency).
Unit of Measure: Score (points)
Measured: Baseline to 12 weeks.
Long-Term Data Donation and Engagement
Sustained participation and data donation patterns among participants who continue sharing data beyond the 12-week period, including frequency of updates and completeness of long-term wearable data.
Unit of Measure: Percentage of expected data points (%)
Measured: Up to 5 years after enrolment.
Mortality Linkage (Optional, CBS Data)
For participants who provide additional consent, linkage of pseudonymised data with official mortality records from Statistics Netherlands (CBS) to evaluate long-term outcomes and population health trends.
Unit of Measure: Mortality status (yes/no)
Measured: Up to 5 years after enrolment.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Nov 2025
- Study startJan 2026 (estimated)
- Primary completionJan 2027 (estimated)
- Study completion1 Apr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiovascular Diseases (CVD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 450 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Nimrat Grewal, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07238036
- Sponsor's protocol ID
- METC 2025.0762
- Acronym
- DDM-TRAIN
- Status last verified
- Nov 2025
- First submitted
- 14 Nov 2025
- Last updated
- 20 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Data Donation Model: Redefining Citizen Participation in Inclusive Cardiovascular Prevention and Care
- ClinicalTrials.gov ID
- NCT07238036
- Acronym / sponsor ID
- DDM-TRAIN / METC 2025.0762
- Conditions
- Cardiovascular Diseases (CVD)
- Keywords
- cardiovascular prevention, data donation, citizen science, health equity, participatory research, digital health, wearable data, lifestyle monitoring
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 450 participants (estimated)
- Lead sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)University, hospital or other
- Study start
- Jan 2026 (estimated)
- Primary completion
- Jan 2027 (estimated)
- Study completion
- 1 Apr 2027 (estimated)
- First posted
- 20 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cardiovascular disease (CVD) is the leading cause of death in the Netherlands and worldwide. While prevention strategies have improved, many population groups, including women, individuals with a migration background, and people with lower socioeconomic status, remain underrepresented in cardiovascular research and prevention programs. As a result, current risk prediction models and lifestyle recommendations are based largely on homogeneous datasets that do not reflect real-world diversity. This structural imbalance limits the generalisability of evidence and contributes to persistent health disparities.
The Data Donation Model (DDM) aims to address this gap by introducing a citizen-led, transparent, and participatory approach to data sharing for cardiovascular prevention and health research. In this model, individuals voluntarily contribute their lifestyle, behavioural, and wearable/app data for research while maintaining full control over consent and use. The DDM incorporates dynamic electronic consent, granular sharing options, and transparency dashboards that allow participants to view how their data contribute to ongoing research projects. This participatory design strengthens trust, autonomy, and inclusiveness in data governance.
This study evaluates the feasibility, inclusiveness, and acceptability of implementing the DDM at scale within the general population. It forms the pilot phase of a broader national data donation infrastructure coordinated by Amsterdam UMC in collaboration with the TRAIN Health Awareness Platform (technical partner) and community organisations. Approximately 450 participants will take part in this first phase, with future expansion planned up to 10,000 citizens.
Participants can connect any wearable device or health app (such as a smart ring, smartwatch, or fitness tracker) to the TRAIN platform and complete short digital questionnaires on lifestyle, sleep, stress, and wellbeing. All participants can donate data for up to 5 years, with the freedom to stop or modify consent at any time. An optional 12-week TRAIN Heart Journey provides guided feedback on physical activity, stress, and recovery patterns, but participation in this module is not required for data donation.
The main outcomes are (1) feasibility and acceptability of the DDM (recruitment, retention, adherence, and user satisfaction), (2) inclusiveness of participation across demographic groups, and (3) trust and engagement with science and data governance. Secondary outcomes include behavioural and physiological changes (activity, sleep, stress) and self-efficacy. Exploratory analyses will evaluate long-term engagement and, for consenting participants, linkage with official mortality data from Statistics Netherlands (CBS).
The findings will inform future national strategies for equitable, citizen-driven cardiovascular prevention and contribute to developing inclusive guidelines based on real-world data from diverse populations.
Detailed description
Background and Rationale Cardiovascular disease (CVD) remains the leading global cause of mortality. Although preventive strategies have advanced, many population groups continue to be structurally underrepresented in research, including people with a migration background, lower socioeconomic status, lower health literacy, and women. As a result, current datasets and risk prediction models do not accurately reflect population diversity, which limits generalisability and contributes to persistent health inequities.
The Data Donation Model (DDM) aims to address these gaps by offering a citizen-driven, transparent approach to sharing lifestyle, behavioural, and wearable/app-derived health data for preventive cardiovascular research. The DDM allows participants to maintain full control over data use through dynamic electronic consent, granular sharing settings, and real-time insight into how their data contribute to research. This approach operationalises ethical principles of autonomy, transparency, and reciprocity, and aligns with modern frameworks for Responsible Data Stewardship and FAIR/Open Science.
Study Purpose This pilot study evaluates whether the DDM can be implemented at scale within the general population. The focus is on operational feasibility, user experience, inclusiveness of participation, and engagement with dynamic consent tools. Results will guide the development of a long-term, citizen-governed data infrastructure for cardiovascular prevention research.
Study Design This is a prospective, observational cohort study with digital enrolment and follow-up. Participation is open to adults from the general population without recruitment through clinical centres. The study infrastructure is hosted on the TRAIN Health Awareness Platform, which facilitates data donation and device/app integration. Approximately 450 participants will be enrolled during this pilot phase.
Participants voluntarily connect one or more wearable devices or health applications of their choice. They also complete periodic questionnaires via the platform. An optional 12-week digital lifestyle module ("TRAIN Heart Journey") is available but not assigned as part of the research design. Data donation may continue for up to five years, depending on individual consent preferences.
Procedures and Data Streams
After electronic informed consent, participants gain access to a personal dashboard where they can:
connect their chosen wearable(s) or health app(s);
manage consent settings;
complete lifestyle and wellbeing questionnaires;
monitor their own engagement and data-sharing status.
Collected data include device-generated behaviour and wellbeing indicators (e.g., activity metrics, sleep patterns, physiological parameters depending on device type), as well as digital questionnaire responses. No biospecimens are collected, and no identifiable data are used for analysis; all data are pseudonymised at source.
Analytical Framework Feasibility will be evaluated using technical performance indicators (data transmission stability, completeness), recruitment and retention characteristics, and participant engagement metrics. Inclusiveness will be assessed using demographic distributions and literacy indicators. Exploratory analyses will focus on long-term participation patterns and-where separately consented-linkage to national mortality records via secure legal frameworks.
Quantitative analyses may include longitudinal modelling of device-based behavioural and physiological signals and descriptive analysis of user-platform interactions. Qualitative and mixed-methods analyses may be used to explore trust, transparency, and participant experience with the DDM.
Data Management and Protection All data handling complies with the General Data Protection Regulation (GDPR). Data are stored in a secure, Health-RI-aligned cloud environment using encryption, pseudonymisation, and role-based access controls. Participants may modify or withdraw consent at any time through the dynamic consent interface. Optional linkage to external datasets (e.g., mortality data) requires additional explicit consent.
Ethical Considerations The Medical Ethics Review Committee determined that the study does not fall under the Dutch Medical Research Involving Human Subjects Act (non-WMO). The study does not involve investigational products or assigned interventions and poses minimal risk. Participation is voluntary and withdrawal has no consequences.
Dissemination Results will be disseminated through peer-reviewed publications, scientific conferences, and citizen-focused communication channels facilitated by the TRAIN Health Awareness Platform and partner community organisations. Insights from this pilot will inform the subsequent scale-up of a national, citizen-driven data donation infrastructure designed to support equitable, population-representative cardiovascular prevention.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| DDM General Population Cohort | – | Other: Digital Lifestyle Feedback Module (optional)This cohort includes adults residing in the Netherlands who voluntarily participate in the Data Donation Model (DDM) through the TRAIN Health Awareness Platform. Participants provide electronic informed consent, connect wearable devices or health apps, and share lifestyle and wellbeing data for up to five years. An optional 12-week TRAIN Heart Journey module offers guided feedback on activity, sleep, and stress, but participation in this module is not required for data donation. Participants can modify or withdraw consent at any time. No randomisation, assignment, or blinding is used. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Adults from the general population voluntarily participating in the TRAIN Health Awareness Platform under the Data Donation Model (DDM). Participants may be healthy or have known cardiovascular risk factors such as hypertension, diabetes, or obesity. Recruitment occurs via digital enrolment, primary care outreach, and community organisations. Participation is nationwide and decentralised, with data collection entirely digital and no site-based visits.
Key inclusion criteria (5 listed)
- Adults (≥18 years)
- Access to a smartphone, tablet, or computer with internet connection.
- Ability to provide electronic informed consent (in Dutch or with supported translation).
- Willingness to contribute lifestyle, health, and/or wearable data through the TRAIN Health Awareness Platform.
- Optional: interest in participating in the 12-week TRAIN Heart Journey for personalised lifestyle feedback.
Key exclusion criteria (4 listed)
- Inability to provide informed consent, even with support.
- Severe cognitive or psychiatric impairment limiting safe participation.
- Inability to use digital devices, even with assistance.
- Concurrent participation in another behavioural or interventional study that could interfere with data collection.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Digital Lifestyle Feedback Module (optional)An optional 12-week digital feedback module offered within the TRAIN platform to participants who choose to engage with guided lifestyle support. This is not an assigned intervention but part of the broader participatory data-donation framework. | Other | DDM General Population Cohort |
Primary outcome
Recruitment Rate
Time frame: From study start until end of recruitment (anticipated 12 months).
Number of participants enrolled per month during the active recruitment period. Recruitment rate reflects the feasibility of enrolling adults from the general population into the Data Donation Model (DDM) via the TRAIN Health Awareness Platform. Unit of Measure: Participants per month
Retention Rate at 12 Weeks
Time frame: From enrolment to 12 weeks after enrolment.
Proportion of enrolled participants who complete the 12-week follow-up period with at least one questionnaire assessment. This measure reflects the feasibility of retaining participants in a fully digital observational study. Unit of Measure: Percentage of participants (%)
Adherence to Wearable and App Use
Time frame: From enrolment to 12 weeks after enrolment.
Proportion of follow-up days with any recorded wearable or app data (e.g., activity, sleep, or heart-rate-derived signals), calculated per participant and summarised at group level. This measure reflects adherence to using the connected device(s) and the TRAIN platform in daily life. Unit of Measure: Percentage of follow-up days with data (%)
Wearable Data Completeness
Time frame: From enrolment to 12 weeks after enrolment.
Proportion of expected data points that are successfully captured and stored for each participant over the 12-week period, based on predefined minimum criteria for valid days (e.g., ≥1 full day of activity and sleep data). This reflects the technical feasibility of continuous data capture within the Data Donation Model. Unit of Measure: Percentage of expected data points (%)
Participant Satisfaction Score
Time frame: At 12 weeks after enrolment.
Overall satisfaction with the Data Donation Model and the TRAIN platform, measured using a brief user experience questionnaire with items rated on a 5-point Likert scale (1 = strongly disagree to 5 = strongly agree). The primary outcome is the mean total score; higher scores indicate greater satisfaction and acceptability. Unit of Measure: Mean score on a 1-5 Likert scale (points)
12 secondary outcomes
Change in Daily Step Count
Time frame: Baseline to 12 weeks.
Change in Active Minutes per Day
Time frame: Baseline to 12 weeks.
Change in Heart Rate Variability
Time frame: Baseline to 12 weeks.
Change in Resting Heart Rate
Time frame: Baseline to 12 weeks.
Change in Sleep Efficiency
Time frame: Baseline to 12 weeks.
Change in Health-Related Quality of Life (EQ-5D-5L)
Time frame: Baseline to 12 weeks after enrolment.
Change in Self-Efficacy (GSES)
Time frame: Baseline to 12 weeks.
Inclusiveness of Participation
Time frame: During and after completion of 12-week period.
Change in Trust in Medical Research
Time frame: Baseline and 12 weeks.
Change in Perceived Transparency
Time frame: Baseline to 12 weeks.
Long-Term Data Donation and Engagement
Time frame: Up to 5 years after enrolment.
Mortality Linkage (Optional, CBS Data)
Time frame: Up to 5 years after enrolment.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Nov 2025.
Related trials for Cardiovascular Diseases (CVD)
Enrolling by invitationObservational study
Multi-Scale Analysis of Phenotypes in Heart Failure (MAP-HEART)
Heart Failure
Recruiting
Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiography SuiTe
Stroke, Acute
Active, not recruitingObservational study
REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure
Aortic Valve Stenosis
RecruitingPhase 1/2
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
RecruitingPhase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiovascular Diseases (CVD), run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 20 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Nimrat Grewal, MD, PhD (+31 20 566 9111, n.grewal@amsterdamumc.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Recruitment Rate (time frame: From study start until end of recruitment (anticipated 12 months).). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Nov 2025.